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Abstract
In a total of 167 respiratory tract specimens from adult outpatients with conﬁrmed Mycoplasma pneumoniae pneumonia, sampled
between 2003 and 2008, and a further 99 isolates obtained from patients between 1991 and 2009 in Germany, M. pneumoniae was
tested for macrolide resistance. Using PCR, real-time PCR and sequencing of the 23S rRNA gene, 1.2% of M. pneumoniae in the respira-
tory tract samples and 3.0% of the isolates were found to be resistant. The results indicate a limited but not negligible importance of
macrolide-resistant M. pneumoniae in the population investigated, which requires the monitoring of macrolide susceptibility of isolates
or the testing of respiratory samples by molecular methods.
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Introduction
Mycoplasma pneumoniae is one of the most common causes
of community-acquired infections of the human upper and
lower respiratory tract and can lead to severe and long-last-
ing interstitial pneumonia [1]. Owing to the fact that myco-
plasmas are cell wall-less bacteria, macrolides are in most
cases the ﬁrst choice for antibiotic treatment of M. pneumo-
niae infections [1]. For young children especially, the alterna-
tives, tetracyclines and new ﬂuoroquinolones, are not
recommended. Resistance of isolated strains to macrolides is
based on point mutations in domain V of the 23S rRNA gene
of M. pneumoniae. An A to G/C transition at position 2063
or 2064 of the gene (M. pneumoniae numbering) resulted in a
high-level macrolide resistance of the M. pneumoniae strain,
whereas a C to G or C to A mutation at position 2617 was
associated with a lower resistance to macrolide antibiotics
[2,3].
Recent occurrence of macrolide resistance was shown in
studies from Japan in which a signiﬁcant increase in resistant
M. pneumoniae strains of up to more than 30% in the year
2006 was reported [4,5]. Results of two current studies from
China showed rates of resistant isolates of 83% and 92%,
respectively [6,7]. In contrast, in an investigation of macrolide
resistance among 155 M. pneumoniae isolates obtained from
patients between 1994 and 2006 in France only two resistant
isolates were found [8]. Furthermore, macrolide resistance
was detected in a relatively low number of M. pneumoniae-
positive respiratory tract samples (ﬁve/100 isolates) in the
United States [9]. A more comprehensive overview of world-
wide macrolide resistance is hampered by the difﬁculty of cul-
tivating M. pneumoniae strains, which has been successful in
reference laboratories only. The use of molecular methods
such as real-time PCR offers the possibility of a culture-inde-
pendent characterization of the circulating M. pneumoniae
strains, including their resistance [4,9]. Furthermore, previous
reports on macrolide-resistant M. pneumoniae have mainly
been concerned with respiratory tract specimens and isolates
from children who were in most cases hospitalized. Although
systematic investigations are not available, differences in the
occurrence of macrolide-resistant M. pneumoniae strains
between adult and paediatric patients cannot be excluded as
preliminary results have suggested [5].
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This is the ﬁrst study to focus on investigating respiratory
tract samples from adult pneumonia outpatients using molecu-
lar methods in order to detect the actual macrolide resistance
in M. pneumoniae found in these specimens. In addition, the
investigation of 100 isolates from patients of different ages
was included to obtain a more comprehensive survey of
macrolide-resistant M. pneumoniae over time in Germany.
Materials and Methods
Respiratory tract samples (bronchoalveolar lavage ﬂuids,
nasopharyngeal or pharyngeal swabs, sputa) were a German
network (Community-Aquired Pneumonia NETwork, CAP-
NET) established to investigate the aetiology of community-
acquired pneumonia. Brieﬂy, 12 local clinical centres
distributed over different regions of Germany cooperated with
a number of general practitioners to systematically collect
samples from patients with symptoms of pneumonia. Between
2003 and 2008, 167 respiratory tract samples of adult pneu-
monia outpatients tested positive for M. pneumoniae [10].
Independent of the specimens sampled within the CAPNET
programme, M. pneumoniae isolates from clinical material
obtained mainly from hospitalized pneumonia patients of
different ages were included in the study. Isolation and propa-
gation of 100 M. pneumoniae strains isolated between 1991
and 2009 from 99 patients (two strains were isolated from
different locations of the bronchial system of one patient, see
below) were carried out as described [11]. DNA from patient
samples and from M. pneumoniae strains grown in Plenrophen-
monia-like organism (PPLO) broth cultures (200 lL each) was
extracted using the QIAamp DNA mini kit (QIAGEN, Hilden,
Germany) according to the manufacturer’s instructions (the
protocol for blood and body ﬂuids called for elution volumes
of 50 and 200 lL, respectively). DNA from patient samples
was pretested using a real-time PCR approach targeting a con-
served part of the gene coding for the main P1 adhesin of
M. pneumoniae [12]. Isolated M. pneumoniae strains and strains
in respiratory specimens conﬁrmed as positive were grouped
into the known subtypes and variants by sequencing a variable
part of the repetitive element RepMP2/3 in the P1 gene of
M. pneumoniae as described recently [10].
For partial ampliﬁcation of the 23S rRNA gene in M. pneu-
moniae-positive respiratory tract samples, the primers (Bio-
mers, Ulm, Germany) MN23SDVF and MN23SDVR (ﬁrst
ampliﬁcation) were used as described [4]. Nested PCR with
the primers MN23SDVFn (5¢-GAC TGT TTA ACT AAA
ACA CAA CTC TAT G-3¢, position: 1777-1804) and
MN23SDVRn (5¢-CTA GAA GCA ACA CTC TTC AAT
CTT C-3¢, position: 2661-2637) was carried out according to
standard procedures (annealing temperature: 60C, 30
cycles) and resulted in an 885-bp product. The 23S rRNA
gene region from DNA from patient isolates was ampliﬁed
with the same primer combination. Speciﬁcity of the PCR
was tested using DNA of the following reference strains: Kle-
bsiella pneumoniae (ATCC 13883), Staphylococcus aureus
(ATCC 25923), Staphylococcus epidermidis (ATCC 12228),
Escherichia coli (ATCC 43895), Pseudomonas aeruginosa
(ATCC 27853), Haemophilus inﬂuenzae (ATCC 49247),
Chlamydophila pneumoniae (strain TW-183), Legionella pneu-
mophila (ATCC 33152), Streptococcus pneumoniae (ATCC
6305), Mycoplasma genitalium (ATCC 33530), Mycoplasma sali-
varium (ATCC 23064), Mycoplasma orale (ATCC 23714),
Mycoplasma hominis (ATCC 23114), Ureaplasma urealyticum
(ATCC 27818), Ureaplasma parvum (ATCC 27815) and Myco-
plasma penetrans (ATCC 55252), respectively. Furthermore,
the DNA of 50 respiratory tract samples of M. pneumoniae-
negative pneumonia patients was included.
An aliquot (1 lL) of the ampliﬁcation product of the
nested PCR (respiratory tract samples) and of the ﬁrst ampli-
ﬁcation (M. pneumoniae strains) was used as template for a
pre-screening real-time PCR for the detection of mutations
at positions 2063 and 2064 of the 23S rRNA gene of M. pneu-
moniae. Ampliﬁcation was carried out using primers
MN23SDVFn and MN23SLCR (5¢-GTA GTA TTC CAC CTT
TCG CAT C-3¢, position: 2183-2162) and probes
MN23SLCP1 (5¢-GTG AAG ACA CCC GTT AGG CGC
AAC-FL, position: 2032-2055) and MN23SLCP2 (5¢-LC640-
GGA CGG AAA GAC CCC GTG-PH, position: 2057-2074).
With a LightCycler 1.5 instrument (Roche, Mannheim, Ger-
many), real-time PCR was performed in a ﬁnal volume of
20.0 lL containing 6.6 lL of water (PCR grade; Roche),
2.4 lL of MgCl2 (25 mM, Roche), 2.0 lL of LightCycler Fast-
Start DNA Master HybProbe mix (Roche), 2.0 lL of each pri-
mer (5 pmol), 2.0 lL of probes (2 pmol) and 1.0 lL of
template. The capillaries were incubated under the following
cycling conditions: pre-incubation at 95C (10 min), 40 cycles
of denaturation at 95C (8 s), hybridization at 57C (8 s) and
elongation at 72C (10 s). Melting curve analysis was carried
out after heating from 55C to 85C (temperature transition
rate: 0.1C/s). Finally, the reactions were cooled to 40C for
30 s. Data were analysed using the LightCycler software ver-
sion 3.5 (Roche). Putative mutations at position 2063/2064 of
the 23S rRNA gene of M. pneumoniae, as suggested by melting
peak analysis, were conﬁrmed by sequence analysis.
Antibiotic susceptibility to erythromycin (Sigma, St Louis,
MO, USA) of M. pneumoniae isolates which were regarded as
macrolide-resistant according to the real-time PCR and
sequencing results was determined by microdilution with
PPLO broth [13]. The MIC was deﬁned as the lowest con-
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centration of erythromycin preventing a colour change of
the medium after an incubation time of 5–7 days.
Results and Discussion
The speciﬁcity of the nested PCR used to amplify the part of
the region of the 23S rRNA gene carrying the known muta-
tions associated with macrolide resistance in M. pneumoniae
was tested with the DNA of seven mycoplasma species
which can be found in humans and nine bacterial species that
commonly cause pneumonia. Ampliﬁcation products were
obtained from M. penetrans and M. genitalium only, which can
be expected from the high identity of the 23S rRNA genes
of the closely related species M. pneumoniae and M. genitalium
(96.7%). None of the 50 M. pneumoniae-negative DNA sam-
ples from pneumonia patients tested gave an ampliﬁcation
product. Despite the fact that M. penetrans and M. genitalium
do not belong to the spectrum of frequent agents of com-
munity-aquired pneumonia, it should be noted that the
nested PCR used was not developed for the primary detec-
tion of M. pneumoniae but is intended as a diagnostic
approach for the further characterization of M. pneumoniae-
positive samples, pre-screened by a sensitive method show-
ing no cross-reaction to other relevant microorganisms.
In contrast, an ampliﬁcation product from the nested PCR
targeting the 23S rRNA was obtained from all 167 investigated
respiratory tract DNA samples pretested as M. pneumoniae-
positive by real-time PCR, conﬁrming the sensitivity of the
approach. Using an aliquot of the PCR product as template in
the real-time PCR, the melting curve analysis of the LC Red
640-labelled detection probe demonstrated clear differences
between amplicons carrying a mutation at position 2063 or
2064 and PCR products with an unchanged 23S rRNA gene of
M. pneumoniae (Fig. 1). Whereas amplicons from macrolide-
susceptible isolates showed a mean Tm of 64.5 ± 0.3C (range,
63.6-64.8C), an A2063G (n = 3) or A2064G (n = 1) mutation
resulted in a mean Tm of the amplicon of 58.9 ± 0.2C. Fur-
thermore, the A2063C (n = 1) and A2064C transition (n = 1)
can be discriminated by an increased Tm of 61.1 and 60.3C,
respectively. Overall, real-time PCR products suggesting a
resistance-relevant mutation in the part of the 23S rRNA gene
described, were obtained from three (3.0%) of the 99 clinical
isolates of M. pneumoniae and from two (1.2%) of 167 M. pneu-
moniae-positive respiratory tract samples (Table 1).
In all cases, the assumed transitions at positions 2063 and
2064 of the 23S rRNA gene were conﬁrmed by sequencing.
Interestingly, in two isolates obtained from the bronchoalveo-
lar ﬂuids from different segments of the bronchi of a hospital-
ized male 35-year-old pneumonia patient, an A2064G change
was detected in one isolate and an A2064C change in the
other. According to the typing scheme based on the sequence
differences in the repetitive elements located in the main P1
adhesin [10], both strains were classiﬁed as subtype 1. This fact
indicates that M. pneumoniae strains with different mutations
in the 23S rRNA gene can be isolated from a single patient.
In previous studies, the MICs of erythromycin, the most
widely used reference macrolide for the detection of M. pneu-
moniae mutants with base changes at position 2063 or 2064
of the 23S rRNA gene, ranged from >400 to 32 mg of eryth-
romycin/L [4–9,14,15]. In the present study, erythromycin
susceptibility testing using microdilution demonstrated that
the four strains with the mutations at these positions are
resistant, with MIC values between >200 and 100 mg of
erythromycin/L (independent of an A2063/2064G or A2064C
transition). In parallel, a limited number (n = 6) of strains
without a change at position 2063 or 2064 were tested and
MIC values between 0.006 and 0.012 mg of erythromycin/L
were found which is in agreement with the data in other
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FIG. 1. Example of the detection of macrolide-resistant Mycoplasma
pneumoniae isolates using real-time PCR amplifying part of the 23S
rRNA gene, followed by melting peak analysis.
TABLE 1. Occurrence of macrolide-resistant Mycoplasma pneumoniae isolates in respiratory tract samples of pneumonia
patients in Germany (without multiple isolations from one patient)
Type of sample
Number
of samples
Macrolide-resistant
M. pneumoniae isolates (%)
Mutation in
23S rRNA gene
Isolation/
sampling year
M. pneumoniae isolates 99 3 (3.0) A2063G (2x)
A2064G
1998, 2006
2005
M. pneumoniae-positive
respiratory tract samples
167 2 (1.2) A2063C
A2063G
2004
2006
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reports [4–9,14]. In contrast, a mutation at position 2617 has
been shown to result in moderate resistance, with MIC values
between 1 and 8 mg of erythromycin/L [3,4]. To assess the
occurrence of this mutation, we sequenced the amplicons
from all of the 167 M. pneumoniae-positive respiratory tract
specimens included in this study. A mutation at position 2617
was not found in any of these cases, conﬁrming the results of
other reports which did not detect any, or only detected a
small portion, of macrolide-resistant M. pneumoniae isolates
with a mutation at position 2617 in comparison with strains
with a change at position 2063 or 2064 [5,7,15]. The
sequenced region of the 23S rRNA gene in all cases shows
100% identity with the corresponding region in M. pneumoniae
(GenBank, BLAST algorithm) and can be clearly differentiated
from the 23S rRNA gene of the most closely related species,
M. genitalium (identity, 97%). This observation further con-
ﬁrms the speciﬁcity of the ampliﬁcation described.
No clear association was observed between macrolide-
resistant isolates or isolates in clinical materials and the sub-
type of M. pneumoniae (two resistant strains were classiﬁed
as subtype 1 and three strains as subtype 2) which is in
accordance with previous results from Japan and China
[4,7,15] and revealed the occurrence of resistant strains in
the two most common genotypes of M. pneumoniae.
In conclusion, the results of the present study demon-
strate the occurrence, in limited numbers, of macrolide-
resistant M. pneumoniae strains in recently sampled respira-
tory tract specimens from adult pneumonia patients and in
isolates mainly from hospitalized patients, in Germany. The
real-time PCR-based method developed is a reliable tool to
detect the most common molecular cause of macrolide
resistance in M. pneumoniae. This approach circumvents the
difﬁcult, insensitive and time-consuming isolation of M. pneu-
moniae from clinical materials and allows resistance screening
in a high number of M. pneumoniae-positive respiratory tract
samples. At the moment, the percentage of resistant strains
in Germany does not justify a re-evaluation of the standard
recommendations for treating community-acquired pneumo-
nia [16]. However, monitoring isolated M. pneumoniae strains
as well as M. pneumoniae-positive clinical materials from
different patient groups seems to be necessary in order to
recognize early changes in the antibiotic resistance pattern of
this important agent of human respiratory tract infections.
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